Elsevier

The Lancet

Volume 341, Issue 8838, 16 January 1993, Pages 134-138
The Lancet

ARTICLES
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect

https://doi.org/10.1016/0140-6736(93)90003-YGet rights and content

Abstract

The relevance of heterozygosity for hereditary protein C deficiency as a risk factor for venous thrombosis has been disputed because heterozygotes without symptoms have been identified among blood donors and relatives of homozygotes. As a result, clinicians do not know whether to offer prophylaxis or not. We have compared thrombosis-free survival in 161 heterozygous and normal members of the families of 24 heterozygotes for protein C deficiency referred from several centres in the Netherlands and with a history of symptoms. We studied the influence of heterozygosity and of putative additional risk factors on the occurrence of thrombotic events noted when a medical history was taken. Protein C activities were measured but a diagnosis of heterozygosity was based on the presence of the specific mutation in one of the protein C genes identified in the proband of the family.

We found a significant difference in the thrombosis-free survival of the 77 heterozygotes and 84 normals: by age 45, 50% of heterozygotes and 10% of normal relatives can be expected to have had a manifestation of venous thromboembolism. The presence of such a mutation was clearly associated with an increased risk of venous thrombotic events. Thrombotic events occurred more often in years in which the patient had been immobile for more than a week or had had surgery. Other putative risk factors showed no significant effect in the incidence of thrombotic events. About 50% of all first episodes and 65% of recurrences of venous thromboembolism in the heterozygotes were spontaneous—ie, there was no predisposing event such as surgery or pregnancy. There was no increased risk for arterial occlusions in heterozygotes. We conclude that members of the family of a symptomatic heterozygote proband who are heterozygous for the mutation in the protein C gene have an increased risk of venous thrombotic events compared with their normal family members. For such individuals prophylactic anticoagulation should be considered; the decision will need to be taken on an individual basis.

References (26)

  • I. Pabinger-Fashing et al.

    Protein C deficiency in two Austrian families

    Thromb Haemostas

    (1983)
  • Mh Horellou et al.

    Congenital protein C deficiency and thrombotic disease in nine French families

    BMJ

    (1984)
  • Cited by (348)

    • Congenital bleeding and thrombotic disorders

      2023, Hemostasis Management of the Pediatric Surgical Patient
    View all citing articles on Scopus
    View full text